These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 18219317)

  • 1. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP; Haase VH
    Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VHL tumor suppressor: master regulator of HIF.
    Haase VH
    Curr Pharm Des; 2009; 15(33):3895-903. PubMed ID: 19671042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIF and other quandaries in VHL disease.
    Tarade D; Ohh M
    Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
    Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
    Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
    Haase VH
    Semin Cell Dev Biol; 2005; 16(4-5):564-74. PubMed ID: 15908240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
    Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
    Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
    Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
    Haase VH
    Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
    Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
    Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
    Chakraborty AA
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets from VHL studies into the oxygen-sensing pathway.
    Maynard MA; Ohh M
    Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K; Zhang N; Zhang K; Na Y
    Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.